Novozymes A/S – (OTCMKTS:NVZMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Marketbeat.com reports. The brokerage currently has a $54.00 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 12.50% from the company’s current price. According to […]
